Table 3.
Conditional Analysis of the MHC Region on 6p21–22 Showing Psoriasis-Specific and Opposing Risk Effects in AD and Psoriasis
| Data Source | Effect | SNV | Pos (hg19) | Allele | HLA Allele/Candidate Genes |
Conditional Modelsa |
Full Model |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AD |
Psoriasis |
poverall |
AD |
Psoriasis |
poverall | ||||||||||
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | ||||||||
| GWAS | PSO | rs111576655 | 31242731 | A/T | C∗06:02 | 0.84 (0.74–0.95) | 0.0053 | 4.41 (4.10–4.74) | 3.1 × 10−376 | 9.8 × 10−380 | 1.12 (0.81–1.54) | 0.5071 | 3.32 (2.90–3.81) | 2.3 × 10−69 | 3.2 × 10−65 |
| GWAS | PSO | rs201374403 | 31383754 | T/TAG | MICA | 0.78 (0.7–0.88) | 6.4 × 10−5 | 1.68 (1.56–1.8) | 7.9 × 10−48 | 2.2 × 10−53 | 0.81 (0.67–0.96) | 0.0174 | 1.65 (1.50–1.81) | 1.8 × 10−25 | 1.0 × 10−26 |
| GWAS | PSO | rs113573479 | 29842444 | A/G | HLA-A | 0.89 (0.81–0.97) | 0.0109 | 1.39 (1.30–1.49) | 6.6 × 10−25 | 1.0 × 10−26 | 0.92 (0.81–1.04) | 0.1948 | 1.41 (1.30–1.52) | 2.8 × 10−17 | 2.7 × 10−17 |
| GWAS | opposing | rs28383201 | 32574869 | C/G | HLA-DRB1 | 0.59 (0.51–0.68) | 4.6 × 10−13 | 1.15 (1.06–1.24) | 4.5 × 10−4 | 3.3 × 10−16 | 0.61 (0.52–0.71) | 3.4 × 10−10 | 1.18 (1.08–1.28) | 1.0 × 10−4 | 6.5 × 10−14 |
| GWAS | opposing | rs1793889 | 31222181 | A/G | HLA-C | 0.60 (0.50–0.73) | 2.5 × 10−7 | 1.18 (1.07–1.31) | 0.0011 | 1.1 × 10−9 | 0.60 (0.50–0.73) | 2.5 × 10−7 | 1.18 (1.07–1.31) | 0.0011 | 1.1 × 10−9 |
| Data Source | Effect | HLA Allele | HLA Allele Frequency in Ps/AD/Controls |
Conditional Modelsa |
Full Model |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AD |
Psoriasis |
poverall |
AD |
Psoriasis |
poverall | ||||||||
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | ||||||
| GWAS | PSO | C∗06:02 | 0.271/0.075/0.089 | 0.81 (0.71–0.91) | 8.48 × 10−4 | 4.28 (3.98–4.61) | 2.9 × 10−362 | 1.30 × 10−368 | 0.97 (0.82–1.15) | 0.7475 | 3.59 (3.26–3.95) | 2.1 × 10−159 | 8.7 × 10−154 |
| GWAS | PSO | A∗02:01 | 0.28/0.227/0.239 | 0.95 (0.88–1.03) | 0.1793 | 1.32 (1.24–1.40) | 4.1 × 10−20 | 1.1 × 10−20 | 0.99 (0.90–1.08) | 0.7739 | 1.32 (1.24–1.41) | 1.8 × 10−17 | 1.1 × 10−16 |
| GWAS | PSO | B∗57:01 | 0.13/0.017/0.032 | 0.61 (0.46–0.80) | 3.83 × 10−4 | 1.63 (1.44–1.84) | 8.0 × 10−15 | 5.8 × 10−20 | 0.60 (0.42–0.85) | 0.0039 | 1.58 (1.38–1.81) | 3.8 × 10−11 | 1.1 × 10−13 |
| GWAS | PSO | C∗12:03 | 0.048/0.044/0.038 | 0.87 (0.74–1.03) | 0.1169 | 1.74 (1.54–2.00) | 5.2 × 10−18 | 3.5 × 10−19 | 0.86 (0.72–1.04) | 0.1295 | 1.85 (1.62–2.11) | 7.5 × 10−20 | 1.8 × 10−20 |
| GWAS | PSO | B∗27:05 | 0.032/0.02/0.025 | 0.80 (0.63–1.01) | 0.0619 | 1.59 (1.37–1.86) | 2.9 × 10−9 | 3.2 × 10−10 | 0.74 (0.55–1.00) | 0.0499 | 1.50 (1.28–1.76) | 7.3 × 10−7 | 1.8 × 10−7 |
| GWAS | PSO | A∗01:01 | 0.221/0.154/0.166 | 1.03 (0.94–1.13) | 0.5475 | 1.25 (1.17–1.35) | 2.3 × 10−10 | 1.7 × 10−9 | 1.08 (0.96–1.21) | 0.2013 | 1.23 (1.14–1.33) | 6.8 × 10−8 | 4.0 × 10−7 |
| GWAS | opposing | C∗03:03 | 0.037/0.025/0.038 | 0.66 (0.54–0.81) | 9.71 × 10−5 | 1.30 (1.13–1.49) | 2.5 × 10−4 | 5.9 × 10−8 | 0.71 (0.56–0.90) | 0.0040 | 1.27 (1.10–1.47) | 0.0011 | 2.3 × 10−5 |
| GWAS | opposing | DQA1∗02:01 | 0.186/0.055/0.098 | 0.64 (0.54–0.76) | 3.44 × 10−7 | 1.09 (1.01–1.19) | 0.0385 | 6.0 × 10−8 | 0.64 (0.54–0.76) | 3.4 × 10−7 | 1.09 (1.01–1.19) | 0.0385 | 6.0 × 10−8 |
Effect allele is underlined. Abbreviations are as follows: PSO, psoriasis; AD, atopic dermatitis. Table shows only independent loci (r2 < 0.5) and the SNV with the strongest association.
a
Stepwise conditional analysis was carried out with multinomial regression models and resulted in three psoriasis-specific and two opposing signals.